Form D · Biotechnology
Sana Biotechnology, Inc.
Seattle, WA · CIK 0001770121
Offering snapshot reported Jun 26, 2020 · SEC filing
- Reported sold
- $45.9M Offering amount: $45.9M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 2, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 26, 2020 | Initial | $45,850,000 | No comparison | 8 | SEC filing |
| Jun 26, 2020 | Initial | $821,097,521 | No comparison | 40 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-369781
Series A-1 Preferred Stock; Common Stock issuable upon conversion thereof
Source: Form D, filed Jun 26, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hans Bishop | Director |
| Douglas Cole | Director |
| Nathan Hardy | Executive |
| Steven D. Harr | Director, Executive |
| Stephen Knight | Director |
| James J. Mac Donald | Executive |
| Richard Mulligan | Director |
| Robert Nelsen | Director |
| Donald Payan | Director |
| Geoffrey Von Maltzahn | Director |
| Mary Agnes Wilderotter | Director |
| Patrick Yang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
188 East Blaine Street, Suit 400
Seattle, WA, 98102
Seattle, WA, 98102